CVE:COT Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis C$0.04 -0.03 (-41.67%) As of 10/14/2020 Add Compare Share Share Stock Analysis Stock Analysis About Cotinga Pharmaceuticals Inc. (COT.V) Stock (CVE:COT) Get COT alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.02▼C$0.12Volume1,000 shsAverage Volume20,281 shsMarket CapitalizationC$769.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada. Read More Receive COT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COT Stock News HeadlinesV BREAKING NEWS: Visa Inc. Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into the Company - VNovember 11, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Inc.May 1, 2024 | wsj.comYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 24 at 1:00 AM | Profits Run (Ad)Lexicon Pharmaceuticals Inc.February 14, 2024 | wsj.comAcumen Pharmaceuticals Inc ABOSNovember 5, 2023 | morningstar.comMSXTP 60 Degrees Pharmaceuticals, Inc.July 21, 2023 | seekingalpha.com8-K: ENANTA PHARMACEUTICALS INCApril 28, 2023 | marketwatch.comIronwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationFebruary 18, 2023 | seekingalpha.comSee More Headlines COT Stock Analysis - Frequently Asked Questions How have COT shares performed this year? Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 at the start of the year. Since then, COT shares have increased by 0.0% and is now trading at C$0.04. Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCVE:COT CIKN/A Webcotingapharma.com Phone+1-519-8585157FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow17.50 Book ValueC($0.18) per share Price / Book-0.20Miscellaneous Outstanding Shares21,986,000Free FloatN/AMarket CapC$769.51 thousand OptionableNot Optionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (CVE:COT) was last updated on 10/14/2020 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredHow I’m playing the AI melt-up (and down)Porter Stansberry says a powerful new market shift is forming and most investors are missing it entirely. I...Porter & Company | SponsoredTrump's bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cotinga Pharmaceuticals Inc. (COT.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Cotinga Pharmaceuticals Inc. (COT.V) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.